Prime Movers Lab Fund I LP's Form 4 filing
Vaxxinity, Inc. (VAXX) · filed Sep 8, 2022
- Accession no.
- 0001062993-22-019372
- Filed
- Sep 8, 2022, 4:55 PM ET
- Trade date
- Sep 6, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market sales total $89.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Prime Movers Lab Fund I LPCIK 0001751631 | 10% Owner |
| Sloss DakinCIK 0001875411 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 | Class A Common Stock | SSaleDisposed | −5,947 | $2.40F7 | −$14,290.05 | 2,226,965 | Indirect | |
| Sep 6, 2022 | Class A Common Stock | SSaleDisposed | −2,234 | $2.40F7 | −$5,368.08 | 836,499 | Indirect | |
| Sep 6, 2022 | Class A Common Stock | SSaleDisposed | −3,934 | $2.40F7 | −$9,453.01 | 1,473,100 | Indirect | |
| Sep 6, 2022 | Class A Common Stock | SSaleDisposed | −25,243 | $2.40F7 | −$60,656.4 | 9,451,674 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F7
The price of $2.4029 per share represents a weighted average of purchase prices ranging from $2.40 to $2.42 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
Referenced by the price of 4 transactions in Table I.